Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Accounts Payables (2021 - 2025)

Verrica Pharmaceuticals has reported Accounts Payables over the past 5 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Accounts Payables at $2.1 million for Q4 2025, up 9.28% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (up 9.28% YoY), and the annual figure for FY2025 was $2.1 million, up 9.28%.
  • Accounts Payables for Q4 2025 was $2.1 million at Verrica Pharmaceuticals, up from $1.6 million in the prior quarter.
  • Over the last five years, Accounts Payables for VRCA hit a ceiling of $2.5 million in Q1 2024 and a floor of $137000.0 in Q3 2022.
  • Median Accounts Payables over the past 5 years was $1.1 million (2024), compared with a mean of $1.3 million.
  • Biggest five-year swings in Accounts Payables: plummeted 84.85% in 2022 and later soared 1305.11% in 2023.
  • Verrica Pharmaceuticals' Accounts Payables stood at $845000.0 in 2021, then tumbled by 40.0% to $507000.0 in 2022, then soared by 386.0% to $2.5 million in 2023, then dropped by 23.05% to $1.9 million in 2024, then grew by 9.28% to $2.1 million in 2025.
  • The last three reported values for Accounts Payables were $2.1 million (Q4 2025), $1.6 million (Q3 2025), and $2.3 million (Q2 2025) per Business Quant data.